Sign In
Buy RAPT
$58.02
+0 (+0%)
At Close: Jun 01, 2026
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
11:25am, Wednesday, 21'st Jan 2026
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
S&P 500 Records Worst Session Since October: Investor Sentiment Dips, Fear & Greed Index In 'Neutral' Zone
01:16am, Wednesday, 21'st Jan 2026
Market sentiment declined as Trump's trade stance intensified fears. CNN Fear and Greed index moved to 'Neutral' zone.
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights
12:40am, Wednesday, 21'st Jan 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Why Rapt Therapeutics Stock Soared Today
05:10pm, Tuesday, 20'th Jan 2026
GSK offered to buy Rapt Therapeutics for a sizable premium to its recent market value. Rapt's experimental antibody therapy could help millions of people who suffer from severe food allergies.
BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
02:34pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
02:13pm, Tuesday, 20'th Jan 2026
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a def
Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
12:15pm, Tuesday, 20'th Jan 2026
MILWAUKEE, Jan. 20, 2026 /PRNewswire/ -- Ademi LLP is investigating RAPT (NASDAQ: RAPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with G
Geopolitical Tensions Extend Broader Market Losses
12:07pm, Tuesday, 20'th Jan 2026
The Dow Jones Industrial Average (DJI) is off 600 points as geopolitical tensions continue to kick off between U.S. and Europe
Major stock indexes sank Tuesday after President Donald Trump threatened to impose new tariffs on eight NATO allies for opposing his desired sale of Greenland to the U.S.
RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition
07:32am, Tuesday, 20'th Jan 2026
Shares of RAPT Therapeutics surged sharply on Tuesday after the biopharmaceutical company said it had agreed to be acquired by British drugmaker GSK in a deal valued at about $2.2 billion, giving the
GSK to buy food allergy drug maker RAPT in $2.2bn deal
07:20am, Tuesday, 20'th Jan 2026
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults
This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.
07:10am, Tuesday, 20'th Jan 2026
Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.
RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders
06:15am, Tuesday, 20'th Jan 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT sh
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough
05:54am, Tuesday, 20'th Jan 2026
GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.
